The journal of mental health policy and economics
-
J Ment Health Policy Econ · Sep 2014
The adoption of pharmaceutical innovation and its impact on the treatment costs for Alzheimer's disease in Taiwan.
As the population ages, the number of people living with Alzheimer's disease (AD) has been increasing over time. Between 1999 and 2006, four new AD drugs were approved for insurance coverage in Taiwan. ⋯ Another potential source of the offsetting effect is that adopting new AD drugs may be beneficial to the reduction in the cost of long-term care. This is an important avenue for future research.
-
J Ment Health Policy Econ · Sep 2014
Association between quality of life and treatment response in children with attention Deficit Hyperactivity Disorder and their parents.
It has been shown that Attention Deficit Hyperactivity Disorder (ADHD) lowers the Quality of Life (QoL) of patients and their families. Medication as part of the treatment has a favourable effect on symptoms as well as functioning. Evidence on the impact of pharmacological treatment on symptoms of ADHD and the QoL of the patient and their family is still limited. There is a need for further research on QoL in ADHD as well as the relationship between ADHD and the impact on families rather than solely on patients. ⋯ Suggestions for further research include the repetition of this study including a control group and obtaining children's self-report on QoL and clinicians report on diagnosis.